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Abstract
Background: The RECIST guidelines are commonly used in phase II and III clinical trials. The
correct definition of response can be controversial in some situations, as in the case we describe.
Case presentation: A 43 year-old man with advanced gastric cancer was enrolled in a phase II
trial where he was treated with pemetrexed 500 mg/m2 plus oxaliplatin 120 mg/m2 every 3 weeks.
At baseline, the target lesions were lymph-nodes, and the non-target lesions were small pulmonary
nodules. At first re-evaluation, the target lesions showed partial response and the non-target
lesions showed complete response, but new diffuse osteoblastic lesions appeared. The investigator
decided to continue treatment until the second re-evaluation. CT scan confirmed the response of
the target and non-target lesions, while the osteoblastic lesions did not change.
Conclusion:  The appearance of osteoblastic lesions after an active antitumor treatment, a
phenomenon known as flare, can complicate the definition of the best overall response using
RECIST criteria. This possibility should be considered by oncologists involved in clinical trials.
Background
Phase II clinical studies that explore the activity of new
drugs or new drug combinations demand a rigorous eval-
uation of tumor response. In the oncology community,
the most commonly used criteria for response evaluation
are contained in the RECIST guidelines [1]. We will
describe here the case of a patient with advanced gastric
cancer who was enrolled in a phase II trial. The evaluation
of the best overall response for this patient has been prob-
lematic using the RECIST criteria, because these criteria do
not contemplate a phenomenon documented in literature
and well known in daily clinical practice called osteblastic
flare.
Case presentation
A 43-year-old man with a history of moderate hyperten-
sion and hypercholesterolemia consulted his physician
for non-specific retrosternal pain. The first diagnostic tests
ruled out myocardial ischemia. Due to the persistence of
the symptoms, the patient underwent endoscopy of the
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upper gastrointestinal tract which revealed the presence of
gastric adenocarcinoma in the antrum and corpus. The
patient underwent a laparotomy. However, the direct
infiltration of the tumor into the pancreatic head and the
presence of small metastatic nodules in the omentum did
not allow for a surgical resection.
At the first examination by the medical oncologist the
patient complained of moderate pain in the epigastric
region with dorsal irradiation and dyspepsia. Codeine
and acetaminophen were prescribed for symptom con-
trol. To complete tumor staging, a contrast-enhanced spi-
ral computed tomography (CT) of the chest, abdomen,
and pelvis was carried out which showed the presence of
three pathological lymph-nodes. The lymph nodes had
diameters larger than 10 mm and were located in the
lesser curvature of the stomach, in the peripancreatic
region, and in the mediastinum. Three pulmonary nod-
ules that were smaller than 10 mm were also observed. A
very small amount of ascites was present in the abdomen,
but neither hepatic nor lytic bone lesions were detected. A
representative bone window scan of the pelvis is shown in
Figure 1A. The results of hematological and biochemical
tests were normal with the exception of serum alkaline
phosphatase, which was 2.5 times the upper limit of nor-
mal.
After a frank discussion of the benefits and the morbidity
of chemotherapy, the patient agreed to enroll in a control-
led phase II trial and was treated with pemetrexed 500
mg/m2 and oxaliplatin 120 mg/m2, both repeated every 3
weeks. The first tumor re-evaluation was carried out 6
weeks after the beginning of the treatment, before the
administration of the third cycle of chemotherapy. The
three lymph-nodes, which were defined as target lesions,
showed a 43% decrease in the sum of the longest diame-
ters, classifying the response as partial. The pulmonary
nodules, which were defined as non-target lesions, were
no longer visible. The bone-window scans, however,
revealed osteoblastic metastases in almost all vertebral
bodies and in the pelvis, as shown in Figure 1B.
From the clinical point of view, the treatment was benefi-
cial to the patient because it led to a significant reduction
in the use of analgesics; moreover, the CA 19.9 level
decreased from 222 U/ml to 66 U/ml.
We reasoned that the observed bone lesions were due to
the strong osteoblastic response of preexisting bone
metastases not visible on the baseline CT scan. In agree-
ment with the patient, treatment was continued for two
additional cycles. At the second tumor re-evaluation 6
weeks later, the target lesions were in confirmed partial
response, and the bone metastases remained stable and
no new blastic lesions appeared.
After the fifth chemotherapy cycle, the patient decided to
go off the protocol because of intolerable side effects, par-
ticularly a pharyngeal disesthesia induced by oxaliplatin.
Two months later, the first follow-up CT showed new
lymph-nodes in the mediastinum and in the mesentery,
while the patient's performance status had deteriorated
due to persistent vomiting. He was then referred to pallia-
tive care.
Discussion
The RECIST guidelines to evaluate response to treatment
in solid tumors are accurate, largely validated, and there-
fore used extensively in clinical trials [1]. However, these
criteria do not take into account the osteosclerotic
changes of bone metastases in response to active antitu-
mor treatment [2,3]. We have described a patient with
A representative bone window scan of the pelvis Figure 1
A representative bone window scan of the pelvis. In A, 
the bone window scan of the pelvis at baseline, before the 
administration of chemotherapy is shown. No clear osseous 
metastasis are seen. In B, the CT scan of the same region 
after two cycles of pemetrexed and oxaliplatin shows diffuse 
osteoblastic lesions which are apparent in the sacrum and 
iliac bones.BMC Cancer 2007, 7:94 http://www.biomedcentral.com/1471-2407/7/94
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advanced gastric cancer who developed osteoblastic
lesions in spite of a partial response after two cycles of
chemotherapy with a regimen of pemetrexed and oxalipl-
atin.
Bone metastases occur in 1% to 11% of patients with gas-
tric cancer; there is no apparent correlation with the histo-
logical tumor type, and the bone sites most frequently
affected are the lumbar and thoracic vertebrae [4].
Chemotherapy can prolong overall survival and improve
quality of life in patients with advanced gastric cancer, but
the long-term results are not satisfactory [5]. It is therefore
important to encourage participation in clinical trials
evaluating new drugs.
The main goal of a phase II trial is to evaluate the objective
response rate of a specific tumor type to an experimental
treatment. According to the RECIST criteria, tumoral
lesions are classified as measurable or non-measurable.
Lesions with a diameter of at least 10 mm, precisely meas-
urable in at least one dimension with spiral CT, belong to
the first group. Non-measurable lesions, on the contrary,
have a diameter less than 10 mm. Lesions which are truly
non-measurable, such as abdominal-pelvic masses, lym-
phangitis, pleural or peritoneal effusion, and bone metas-
tases also belong to this group [1].
Depending on the prevailing osteoclastic versus osteob-
lastic cellular activity, imaging techniques can identify
bone metastases as lytic, blastic, or mixed. Distinct aspects
of bone tissue can be visualized with different imaging
approaches. Conventional radiography and CT visualize
bone structure. Tumor and bone marrow can be visual-
ized with magnetic resonance imaging. Osteoblastic bone
metabolism can be visualized with skeletal scintigraphy,
and tumor metabolism by positron emission tomography
[6]. The existing standardized criteria from UICC and
WHO for response assessment of bone metastases are
based exclusively on conventional radiology and skeletal
scintigraphy.
In the clinical case described here, the symptoms reported
at initial presentation did not point to bone metastases.
Furthermore, the standard examination protocols for
asymptomatic cases like this one do not envisage skeletal
scintigraphy. Therefore, the only indication of possible
diffusion of the disease to bone was increased serum alka-
line phosphatase.
Tumor re-evaluation after two cycles of chemotherapy
indicated a partial response in the lymph-nodes identified
as target lesions, and a complete response in the small
pulmonary nodules identified as non-target lesions. Nev-
ertheless, according to strict application of the RECIST cri-
teria, the overall response could have been disease
progression because of the appearance of new osteoscle-
rotic lesions.
For decades, effective antitumor treatments have been
known to increase the bone density of osteolytic metas-
tases. Therefore, the appearance of new osteoblastic
lesions is always difficult to interpret [7,8]. Skeletal scin-
tigraphy is useful in some cases, but does not allow for a
quantification of treatment response, and its application
is limited by a phenomenon known as scintigraphic flare
[9].
The RECIST guidelines do not take osteoblastic changes
into account when treatment response is assessed. How-
ever, this possibility should be carefully considered,
because an incorrect definition of disease progression can
lead to the untimely interruption of a potentially benefi-
cial treatment.
Outside the context of a clinical trial, oncologists usually
weigh the treatment response of bone metastases against
the beneficial effects of treatment on symptoms, and on
the decrease of tumor markers. The decision whether to
continue treatment depends mostly on the oncologist's
experience rather than on published criteria [6].
In this clinical case the flare phenomenon was independ-
ent on the experimental treatment, pemetrexed and oxali-
platin. Therefore the occurrence of an osteoblastic
response should be taken into consideration even in case
of patients treated with standard cytotoxic regimens for
gastric cancer, such as epirubicin, cisplatin and fluorour-
acil (ECF).
The patient described here received an effective treatment
for two additional months before discontinuing due to
cumulative toxic effects. Unfortunately, as is usually the
case for advanced gastric cancer, the duration of response
was very short. However, in patients with breast or pros-
tate cancer the correct identification of an osteoblastic
healing response to systemic treatments could lead to
long-term clinical benefit [9].
Conclusion
The RECIST criteria are frequently used to assess response
in clinical trials investigating new treatments for solid
tumors. However, the RECIST criteria are imperfect in pre-
cisely measuring tumor response and progression, and fall
short in some situations and with some types of cancer
therapeutics [10]. For this reason, it is important to report
controversial cases that physicians often face in the con-
duct of phase II clinical studies. We believe it is reasonable
for a phenomenon such as osteoblastic flare to be consid-
ered in the next version of RECIST guidelines.Publish with BioMed Central    and   every 
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